DcR3对肝癌细胞生长迁移的影响  

The influence of DcR_3 on the growth and migration of hepatocellular carcinoma cell line hepG_2

作　　者：陈罡[1] 罗殿中[1] 党裔武[1] 

机构地区：[1]广西医科大学病理教研室,广西医科大学第一附属医院病理科,南宁530021

出　　处：《陕西医学杂志》2009年第3期344-347,共4页Shaanxi Medical Journal

基　　金：中国高等学校博士学科点专项科研基金(20050598005);广西科学研究与技术开发计划应用基础研究项目基金(桂科基0639040);广西科学研究与技术开发计划课题(桂科能05112001-4D)

摘　　要：目的:观察将DcR3中和性抗体加入肝癌细胞系hepG2后,细胞生长增殖、运动迁移等生物学特性的变化。方法:将DcR3抗体加入hepG2中,MTT检测不同浓度抗体作用于hepG2存活率,挑选最佳作用时间和浓度;免疫细胞化学检测DcR3抗体加入后hepG2 DcR3蛋白表达差异;通过绘制生长曲线及集落形成实验分析生长增殖特性;流式细胞仪(FCM)检测其对细胞周期的影响;划痕实验分析DcR3对hepG2迁移能力的影响。结果:DcR3抗体最佳实验浓度为0.8mg/L,作用时间48h。加入DcR3抗体后,HepG2 DcR3蛋白表达明显减弱;细胞生长增殖能力和集落形成能力均显著下降;细胞周期阻滞在G1/S期;同时迁移能力也明显被抑制。结论:DcR3中和性抗体能显著抑制肝癌细胞的生长和迁移,提示该基因在肝癌的发生发展及浸润转移中发挥重要作用,其中和性抗体有望在临床治疗中应用。Objective： To observe the changes of the growth, proliferation and transference in the hepatocellular carcinoma cell line hepG2 with neutralization antibody DcR3（DcR3-Ab） intervention. Methods： DeR3-Ab was added into hepG2 and the ceil livability rate was detected to search for the best working time and concentration of DeR3-Ab by MTT assay. The difference of DcR3 protein expression in hepG2 was checked by immunocytochemistry after adding DcR3-Ab. The cellular proliferation was examined bycell growth curve and colony formation assay; The changes of cell cycle were analyzed by flow cytometry （FCM）; The transferring ability was investigated by the wound healing test. Results： The best concentration of DeR3-Ab was 0. 8mg/L, best time was 48h; The DcR3 protein expression weakened in HepG2 with DcR3-Ab adding; The cell viability, growth speed and colony formation ability decreased obviously by adding DcR3-Ab. The progression of the cell cycle was arrested in G1/S-phase remarkably induced by DcR3-Ab. The transferring ability was significantly inhibited. Conclusions： The experimental results show that DcR3-Ab can restrain the growth and movement of the hepatocellular carcinoma cells. The DcR3 gene plays an important role in origination, progression and metastasis of liver cancer and it is hopeful to be applied in the future clinical therapy to hepatocellular carcinoma.

关 键 词：肝肿瘤/病理学 @DcR3 细胞运动 细胞分裂 @中和性抗体 

分 类 号：R735.7[医药卫生—肿瘤] R392.9[医药卫生—临床医学]